Chemomab Therapeutics (CCMB) Corporate presentation summary

Nebokitug clinical development and positioning

• Nebokitug is a first-in-class, Phase 3-ready monoclonal antibody targeting CCL24, with first-to-market potential for primary sclerosing cholangitis (PSC), a rare liver disease with high unmet need and >$1B commercial opportunity.

• Positive Phase 2 data in PSC demonstrated safety, anti-fibrotic, anti-inflammatory, and anti-cholestatic activity, derisking the Phase 3 program.

• FDA End-of-Phase 2 meeting provided a clear, efficient pathway to full approval, with a single event-driven pivotal trial using a composite clinical endpoint.

• Nebokitug also has a Phase 2-ready program for systemic sclerosis (SSC), another orphan disease with >$1.5B potential.

• Orphan Drug and Fast Track designations in both PSC and SSC support regulatory and commercial advantages.

Mechanism of action and scientific rationale

• Nebokitug neutralizes CCL24, a chemokine central to inflammation and fibrosis, directly activating fibroblasts and immune cell recruitment.

• Preclinical and patient sample data show elevated CCL24 in PSC and SSC, correlating with disease severity and progression.

• Animal models and ex vivo studies confirm anti-fibrotic and anti-inflammatory effects across multiple organs.

• Nebokitug’s direct CCL24 inhibition offers advantages over receptor blockade, including favorable tolerability and reduced off-target effects.

Phase 2 SPRING trial results in PSC

• Randomized, double-blind, placebo-controlled trial in 76 PSC patients showed good safety and tolerability at both 10 mg/kg and 20 mg/kg doses.

• Statistically significant improvements in liver stiffness, ELF score, fibrotic biomarkers, pruritus, and bilirubin, especially in moderate/advanced disease at 20 mg/kg.

• 48-week open-label extension confirmed durability of anti-fibrotic effects, reduced progression of liver stiffness, and fewer clinical events versus historical controls.

• Safety profile remained favorable over 48 weeks, with most adverse events mild and similar across arms.